Fauci’s Remdesivir Costs $9 Per Dose, Will Be Sold at $3,000 Per Treatment

Pixabay
image_pdfimage_print
The Association of American Physicians and Surgeons filed a lawsuit against Department of Health and Human Services and the FDA for “irrational interference” by the FDA with timely access to hydroxychloroquine (HCQ), which has shown great success in treating Covid-19. HCQ is being sidelined despite having been approved for malaria in 1955, it is reported to be 91% effective in treating COVID-19, and it is inexpensive, costing only $1 per treatment to manufacture. All but four states have imposed restrictions on outpatient use of this drug. Major pharmaceutical companies (Novartis, Bayer, Teva, and others) donated nearly 50-million doses of HCQ to the Strategic National Stockpile, but most of it still sits in warehouses because state governments are preventing its use.

Dr. Fauci has been promoting remdesivir, which has only shown modest results with COVID-19 patients, despite taxpayer funding $70-million to Gilead pharmaceutical, the CDC, and the National Institutes of Health to develop it as a treatment for Ebola, which flopped due to severe side effects and almost zero curative effect. Patients must be hospitalized in order to receive remdesivir. Bloomberg reported that the cost to manufacture remdesivir is $9 per treatment, but Gilead said it will cost over $3,000 for a six-vial treatment. Gilead spent over $5-million in lobbying Congress in 2019. -GEG

At the Presidential Briefing on Apr 30, Dr. Anthony Fauci announced early results, prior to peer-review, of one clinical trial using remdesivir, an intravenous (IV) experimental antiviral medicine in patients hospitalized with COVID-19. At the “warp speed” currently in vogue for the Fauci-led push to a new vaccine, the very next day the FDA issued an Emergency Use Authorization (EAU) for remdesivir to be used in seriously ill hospitalized patients. To announce the emergency approval, President Trump met with the CEO of the drug’s manufacturer, Gilead Sciences, in the Oval Office.

Such rapid authorization is quite unusual with the FDA. Unlike the experimental remdesivir with no prior FDA approval, hydroxychloroquine (HCQ) required two months from reports of successful use in China and South Korea to get the Mar 28 FDA EUA for use in hospitalized COVID-19 patients. HCQ was approved in 1955 for malaria, and later for lupus and rheumatoid arthritis. Over the last 65 years, hundreds of millions of prescriptions have been written for HCQ worldwide.

The EUA for HCQ did not, however, expand its availability but imposed restrictions to prevent non-hospitalized patients from accessing the government’s stockpile of the drug. Democrat Governors Cuomo (NY), Sisolak (NV), and Whitmer (MI), then imposed restrictive orders on outpatient use, and all but four states have followed their lead.

In decades of widespread use, HCQ has an impressive safety record. Irregular heart rhythm or damage to the retina occur rarely, usually with high doses used long term. FDA shows only 62 cardiac deaths attributed to HCQ out of more than 50 million prescriptions, or 0.000124 percent (1.2 out of each 1 million Rx). Rheumatology guidelines for lupus and rheumatoid arthritis do not even require baseline electrocardiograms before prescribing HCQ, since the risk is minimal.

Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.

Early results of the first clinical trial of remdesivir against placebo in coronavirus were announced at the White House Apr 30, and showed modest benefits, according to The New York Times. Surviving patients given remdesivir were discharged 4 days sooner than patients given placebo, though no criteria were given for determining improvement. Death rates were not significantly different. About 25 percent of patients receiving remdesivir had potentially severe side effects, including multiple organ dysfunction, septic shock, acute kidney injury, and low blood pressure. Another 23% showed evidence on lab tests of liver damage.

Gilead’s own press release revealed the side effect of acute respiratory failure in 6 percent of patients in the remdesivir 5-day treatment group, and 10.7 percent of patients in the 10-day treatment group, clearly ominous findings with a drug designed to treat respiratory failure caused by COVID-19.

Dr. Steven Nissen, Cleveland Clinic cardiologist who has conducted dozens of clinical trials, explained to The New York Times: “The disclosure of trial results in a political setting, before peer review or publication, is very unusual. Scientists will need to see figures on harms associated with the drug in order to assess its benefits…. This is too important to be handled in such a sloppy fashion.”

Dr. Michele Barry, a global health expert at Stanford University, expressed concern about Dr. Fauci’s overly enthusiastic praise for remdesivir: “It is unusual to call a drug the ‘standard of care’ until peer review of data and publication, and before studies have shown benefit in mortality.

The leading communicable disease specialist in France, Professor Didier Raoult,  asked about another odd aspect of the remdesivir trial: “Could Anthony Fauci explain why the investigators of the NIAID remdesivir trial did change the primary outcome during the course of the project?” Death as the primary outcome was moved to a secondary outcome, and days to recovery became the primary trial outcome. Changing the primary outcome before trial results are completed is highly unusual and suggests “p-hacking”—manipulating the data to get a statistically significant “p value.”

In contrast, the multi-country compilation of evidence on HCQ and azithromycin in treatment of COVID-19  (updated Apr 27, 2020) has consistently shown that these older medicines prevent infections, significantly reduce severity of illness, reduce viral load and duration of infectivity, reduce number of hospitalizations, reduce ventilator use, and markedly reduce deaths. The data is far beyond “anecodotal,” as Dr. Fauci dismissively called it.

Money appears to be trumping medical wisdom in the recent enthusiasm for remdesivir based on just one study with modest results. One naturally wonders whether this may have anything to do with the fact that the “world’s largest asset manager,” BlackRock, owns the largest share of all Gilead stock at 8.4%. BlackRock’s influence in Washington, D.C., is legendary, and it recently was awarded the financial crown jewel of administering the Federal Reserve’s $4.5 Trillion COVID-19 loan bail-out program.

Read full article here…

Additional source:

STUNNING: Fauci’s Remdesivir Costs $9 Per Dose, Will Be Sold at $3,000 per Treatment — China Company Linked to Soros Will Also Mass Produce the Drug

Visit our Classified ads.

Check out our Classified ads at the bottom of this page.

Recent stories & commentary

Freedom

NBC Employs Researcher to Dox Trump Supporters

October 23, 2020 Revolver and Fox News 2

Brandy Zadrozny, an online researcher with NBC News, says her job is to seek out personally identifying information on anonymous Trump supporters. She has access to third-party dark data vendors who monitor and sell internet users’ personal information. Recently, she has targeted QAnon, a movement that supports Trump.

Classifieds

For classified advertising rates and terms, click here. The appearance of ads on this site does not signify endorsement by the publisher. We do not attempt to verify the accuracy of statements made therein or vouch for the integrity of advertisers. However, we will investigate complaints from readers and remove any message we find to be misleading or that promotes anything fraudulent, illegal, or unethical.

Subscribe
Notify of
guest
8 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Joe Schmo
Joe Schmo
3 months ago

The scoundrels make money while killing a certain percentage of people with lethal side effects. It’s a win-win for eugenicists.

Jim
Jim
3 months ago

Fauci would be a Ferengi (fictitious greedy alien) hero. He seems to follow as many of the Ferengi Rules of Acquisition as he possibly can. I never trusted his double-speak, lies and constantly changing stories to hard sell bargain basement science products at premium – high profit – prices on the American people. There are already cures that are being suppressed: Hydroxychloroquine, Quercitin 500mg (works like a zinc ionophore – article in Mercola website), Chlorine Dioxide, or MMS (see NIH study in Ecuador 100% cure rate), various other treatments/vitamin supplements out there also.

Jim
Jim
3 months ago

Also, colloidal silver in a nebuliser might be the best lung treatment out there. Where are the studies that don’t have a conflict of interest?

terry shead
terry shead
3 months ago

Surely no one in there right mind is going to take any of this crap put out by these phony drug companies, unless you want to die or be tracked around the world.

Jason Martin
Jason Martin
3 months ago

Typical government invention. Don’t let us use one that works, make people use the expensive one that Dr. Fauci gets a cut of. So typical of the medical community. All drugs should be available for purchase. Competition would set the price…

Joe
Joe
3 months ago

I find most of your sites to be very informative. The one re inexpensive and dependable medication for carona virus needs to bee seen by everyone. I will pass it on to my friends.

Ed
Ed
3 months ago

Little Mr. Fahucci is a paranoia broker and a profiteer. He is no Dr.

trackback
What Are Zombie Corporations? – Investing Video & Audio Jay Taylor Media
3 months ago

[…] a leg to have it administered… Guess which one is moving to the top? All that can be found here: https://needtoknow.news/2020/06/faucis-remdesivir-costs-9-per-dose-will-be-sold-at-3000-per-treatmen…   Or, here’s your snippet: “The Association of American Physicians and Surgeons filed a […]